ANTX: Failed Drug, Fading Squeeze, Expiring Shelf

I developed a machine learning model that assigns a risk score to over 3,000 small-cap stocks to identify shorts. As of today, the #1 stock by risk score is ANTX. It recently ran from $1.06 to $6.91 on no news before fading to $3.77. During the run-up, management repriced their out-of-the money options to within the new price range, signaling intent to sell. The company has huge unused shelf capacity that is about to expire, and they need to raise cash because they have no revenues. Their top drug candidate just failed a clinical trial. If you want to know more, all of this is detailed in a research report that is available at Shortfinder (free registration required). I currently have no position in ANTX.